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Abstract
Background: Salivary ductal carcinoma (SDC) of parotid gland is a rare and aggressive entity; accounting for 1–3 % of
all malignant salivary gland tumors, 0.2 % of epithelial salivary gland neoplasms, 0.5 % of salivary gland carcinomas, and
1.1 % of parotid gland carcinomas. Here in we aimed to evaluate the clinico-pathological features and treatment
outcomes of parotid gland SDC in Saudi population.
Methods: Among 38 patients with parotid malignancies, who were treated in two major tertiary care referral cancer
centers between December 2007 and December 2014, seven cases (18.4 %) were found to have SDC, which were
investigated for clinicopathological features, locoregional recurrences (LRRs), distant metastasis (DM) and survival rates.
Results: Mean age of cohort was 62.3 years (range: 41–83) and female predominant (71.4 %). All patients underwent total
parotidectomy and ipsilateral neck dissection. Mean tumor size was 3.4 cm (range: 2.1–5.3); perineural invasion (85.8 %);
lymph node involvement (42.9 %); and HER-2 neu overexpression (28.6 %). Postoperative radiation therapy (PORT) was
given to six patients (dose: 50–66 Gy). Median follow-up was 20.2 months (range: 11–48). LRRs were seen in five (71.4 %)
patients (base of skull, 3 patients; cervical nodes, one patient; parotid bed, one patient). LRRs were salvaged with resection
(two patients) and re-irradiation (one patient with base of skull). DM in lungs was seen in three patients (42.8 %); one
treated with carboplatin/paclitaxel based chemotherapy. The 4-year disease free and overall survival rates were 16.7 %
and 40 % respectively.
Conclusion: SDC of parotid gland is a rare and aggressive entity, and most of LRRs were seen in the base of skull, which
warrants inclusion of base of skull in clinical target volume in PORT planning. Role of anti HER-2 targeted therapy in SDC
with HER-2 neu overexpression needs further investigations.
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Background
Salivary ductal carcinoma (SDC) of parotid gland is a
rare and aggressive entity; accounting for 1–3 % of all
malignant salivary gland tumors, 0.2 % of epithelial saliv-
ary gland neoplasms, 0.5 % of salivary gland carcinomas,
and 1.1 % of parotid gland carcinomas [1, 2]. SDC of
parotid gland has been classified as high grade tumors
along with high-grade mucoepidermoid carcinoma and
carcinoma ex pleomorphic adenoma in the updated
World Health Organisation (WHO) classification of
salivary gland tumors [3]. The histopathological features
of SDC of parotid gland are similar to those of breast
ductal carcinoma requiring a differential diagnosis with
possible metastasis through immunohistochemistry
(IHC) analysis among patients with a previous history of
breast carcinoma [4].
The standard treatment for SDC of parotid gland is
total parotidectomy, ipsilateral neck dissection followed
by postoperative radiation therapy with or without con-
current chemotherapy; however, SDC of parotid gland
has grave dismal prognosis [5].
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Here in, we describe and discuss the clinicopathologi-
cal characteristics and treatment outcomes SDC of par-
otid gland in our population.
Methods
After formal approval from the institutional review com-
mittee, medical records of 38 patients with confirmed
parotid gland malignancies, who were treated in two
cancer centers of Riyadh, Saudi Arabia during the period
of December 2007 and December 2014, were reviewed
using digital database system. Patients with SDC of par-
otid gland were retrieved in following manner;
Demographic, clinicopathological and radiological
variables
Demographic and clinical data including age at the diagno-
sis, gender, and signs and symptoms at the time of presen-
tation were reviewed. A detailed second review of all
histopathological specimens was performed by experienced
histopathologist. Different histopathological parameters,
including the tumor size, lymphovascular space invasion
(LVSI), perineural invasion (PNI), margin status, lymph
node involvement and tumor, lymph node and metastasis
(TNM) staging were recorded. Data from different imaging
modalities, including computed tomography (CT) scan of
neck and chest, magnetic resonance imaging (MRI) and
flourodeoxyglucose positron emission tomography (FDG-
PET) was collected. Data regarding different treatment
modalities, including the type of parotidectomy and neck
dissection, postoperative radiation therapy (PORT), and its
doses were also recorded.
Statistical analysis
The primary endpoint was locoregional control (LRC). Sec-
ondary points were the distant metastasis control (DMC),
disease free survival (DFS) and overall survival (OS) rates.
Locoregional recurrence (LRR) was defined as, the duration
between the parotidectomy and the date of clinically or
radiologically detectable disease in the parotid bed or in
cervical lymph nodes on imaging. Distant metastasis (DM)
was defined as, the duration between the parotidectomy
and the date of documented disease outside the neck on
imaging. Similarly, DFS was defined as, the duration be-
tween the parotidectomy and the date of documented dis-
ease reappearance/relapse, death from cancer and/or last
follow-up (censored). The OS was defined as, the duration
between the surgery and the date of patient death or last
follow-up (censored). Probabilities of LRC, DMC, DFS and
OS rates were shown with the Kaplan-Meier method, and
the comparisons for various survival curves were per-
formed using log rank. All statistical analyses were per-
formed using the computer program SPSS version 16.0.
Relevant literature was searched through PubMed/MED-
LINE, CANCERLIT, EMBASE, Cochrane Library database,
Web of Science, Academic Search Premier, and CINAHL
using the terms “(salivary duct carcinoma, ductal carcinoma
parotid, Stensen duct carcinoma of parotid. These terms
were then combined for search for prospective, retrospect-
ive, randomized, controlled, review articles.
Results
Among thirty eight patients with parotid malignant tu-
mors who were treated in our centers between Decem-
ber 2007 and December 2014, seven cases (18.4 %) were
found to have SDC. Mean age of cohort was 62.3 years
(range: 41–83), with female preponderance (71.4 %). The
common presentation at the diagnosis was the parotid
swelling. In two patients (28.6 %), facial nerve palsy was
seen at the time of diagnosis. Patient characteristics are
shown in Table 1.
All patients underwent total parotidectomy and modi-
fied ipsilateral neck dissection. Mean tumor size was
3.4 cm (range: 2.1–5.3). Predominant histopathological
pattern was the neoplasm was comprised of cribriform
growth pattern with central comedo necrosis, and tumor
cells were polygonal with distinct cell borders, with pleo-
morphic nuclei and increased mitotic activity (Fig. 1a
and b). PNI was observed in 6/7 cases (85.8 %), while
LVSI was seen in 3/7 patients (42.9 %). Lymph node in-
volvement was observed in 3/7 cases (42.9 %). HER-2
neu was overexpressed in 2/7 cases (28.6 %).
PORT via IMRT was given to 6/7 cases (85.8 %). In-
dications were positive margins (66.7 %), and lymph
node metastasis (50 %). Median delay between surgery
and PORT was 6 weeks (range: 5.5–8). The treatment
fields encompassed the tumor bed and upper neck (4
patients), and tumor bed and entire neck (2 patients).
Cranial border of PORT fields were kept at base of
skull in 2 patients. Mean dose for PORT was 61.3 Gy
(range: 50–66 Gy), given as daily 2 Gy/fraction, 5
days/week over 6–6.5 weeks (30–33 fractions).
Median follow-up was 20.2 months (range: 11–48).
LRRs were seen in five (71.4 %) patients. One LRR was
in patient without PORT, Two LRRs were marginal near
PORT fields (mastoid air cells/base of skull; 3 patients)
Fig. 2a and b; two LRRs were seen in-field PORT (cer-
vical nodes; one patient, parotid bed; one patient)
Fig. 3. LRRs were salvaged with resection (two pa-
tients) and re-irradiation via IMRT (one patient with
base of skull recurrence) and systemic chemotherapy
(one patient). DM in lungs was seen in three patients
(42.8 %); one treated with carboplatin/paclitaxel based
chemotherapy. At the time of analysis, four patients
(57.2 %) were alive and were disease free. The median
time to survival was 15.8 months. The 4-year LRC,
DMC, DFS and OS rates were 20.8 %, 40 %, 16.7 %
and 40 % respectively Fig. 4a and b.
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Table 1 Patient characteristics
Patient Age
/gender
Symptoms Treatment Pathology Recurrence Metastasis Died Follow-up
period





Tumor size: 2 × 3 cm; LVSI -: PNI-;
0/20 LN; HER-2 neu +++; Margins-;
Base of skull with ICE (VI,VIII,IX,X,XI CN
palsy) Treated with Palliative RT 25
/10
Bilateral Lungs Yes 14 months
2. 41/M Right parotid
swelling
Total parotidectomy +
ipsilateral MND→ RT 60 Gy/
30 fractions
Tumor size: 3 × 3 cm,; LVSI-, PNI+; 0/
30LN; HER-2 neu +++; margins-
No No No 11 months
3. 83/M Right parotid
swelling
Total Parotidectomy +
ipsilateral MND→ RT 50 Gy/
25 fractions
Tumor size: 2 × 2 cm,; LVSI-;PNI+; 0/
10 LN; HER-2 neu -; margins+,
No Bilateral Lungs Yes 13 months
4. 43/F Right parotid
swelling
Total parotidectomy +
ipsilateral MND→ 66 GY/33
fractions
Tumor size: 4 × 3 cm,; LVSI+; PNI+;
HER-2 neu -; skin +; 2/30LN+; mar-
gins+
Mastoid air cells and base of skull
Treated with Reirradiation 60 Gy/30
fractions
No No 27 months
5. 65/F Right parotid
swelling
Total parotidectomy +
ipsilateral MND→ RT 66 Gy/
33 fractions
Tumor size: 4 × 4 cm; LVSI-; PNI+;
HER-2 neu -; 5/14 LN+; margins+,
Ipsilateral Neck nodes level III, IV
Treated with salvage LND
No No 12 months




ipsilateral MND→ RT 66 Gy/
33 fractions
Tumor size: 5 × 5 cm; LVSI+; PNI+;
HER-2 neu -; 3/21LN+; margins +
Mastoid air cells and base of skull
treated with chemotherapy




7. 71/F Left parotid
swelling
Total parotidectomy +
ipsilateral MND→ RT 60 Gy/
30 fractions
Tumor size: 3 × 3 cm; LVSI +; 0/
22LN; PNI+; HER-2 neu -; margins-
Tumor bed Treated with resection
Pathology 1.2 cm SDC
No No 48 months




















SDC is an extremely rare and aggressive malignancy of
the salivary glands. Owing to its rare nature, clinical data
is scanty and only a few clinical studies comprise more
than 50 SDC patients [4, 6–8]. To date, largest SDC
study has been reported from the Surveillance, Epidemi-
ology, and End Results (SEER) database, based on 228
patients [9]. This review reported that poor prognostic
factors for OS and DFS in SDC patients were age
50 years or above, tumor size, and lymph node involve-
ment. However, this study was criticized for the diagnos-
tic bias. Similar other studies have been mentioned in
Table 2 [3, 4, 6–8, 10–21]. However, none of these stud-
ies has evaluated clinico-pathological features, DFS and
OS in SDC of the parotid gland separately, which was
the aim of present study. Reason for lower incidence of
facial nerve involvement at the time of diagnosis
(28.6 %) in our series as compared to reported data can
be explained by the fact that the preoperative facial
nerve function was not available for many patients, so
facial nerve sacrifice at the time of parotidectomy was
used as a surrogate for preoperative facial nerve palsy.
Our series was predominantly female gender (71.4 %),
which is in agreement with one study by Hosal AS et al.
[15], while other studies have shown a male preponder-
ance ranging from 53.8 % to 94.7 % [11, 19]. In present
study, relatively high incidence of pathological positive
cervical lymph nodes (42.9 %) was found in agreement
with reported literature, and it warrants routine use of
prophylactic ipsilateral neck dissection in SDC of the
parotid gland. Similarly, the percentage of pathologically
positive PNI (85.8 %) was significantly high in our series,
which supports the notion that CTV should include the
cranial nerves involved and the corresponding parts of
the base of skull in cases of pathologically positive PNI
[22]. Interestingly, in our series, no contralateral neck
recurrence was seen, therefore the role of prophylactic
contralateral neck irradiation needs further investigation.
HER-2 neu overexpression (28.6 %) was much lower than
those reported in literature [3, 6, 13]. Recent data has
shown that HER-2 neu overexpression and targeted therapy
with Trastuzumab therapy is associated with improved DFS
and OS rates [23]. Given the limited published data on use
of adjuvant or maintenance Trastuzumab in SDC of parotid
Fig. 2 a CT head axial image (patient # 1) showing a destructive recurrent mass in the right sphenoid wing, extending into middle and posterior
cranial fossae with destruction of a large portion of the skull base; b CT head (patient # 4) demonstrating heterogeneous soft tissue recurrent mass
involving the right mastoid air cells, mastoid bone and occipital bone associated with bone destruction
Fig. 1 a Neoplasm is comprised of cribriform growth pattern with central comedo necrosis (H & E stain, 200 X magnifications); b neoplastic cells have
polygonal morphology, distinct cell borders, moderately pleomorphic nuclei and increased mitotic activity (H & E stain, 400 X magnifications)
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gland, it might also be useful to develop future Trastuzu-
mab trials in SDC from HER-2 neu positive breast cancer
[24]. As SDC of parotid gland has morphologic and mo-
lecular similarity to breast cancer, it is recommended that
apart from regular histopathological examination, add-
itional immunohistochemical staining including HER-2
neu, Ki-67, p16, p53, estrogen receptors (ER), progesterone
receptors (PR), epithelial membrane antigen (EMA), and
carcinoembryonic antigen (CEA) should be performed, as
proposed by many studies [25, 26].
In contrast to other studies, about 60 % of LRRs were
seen in base of skull (PORT was given in 2 patients) in
our series, which further supports the hypothesis of in-
clusion of base of skull in CTV during PORT for these
patients as in patients with parotid gland adenoid cystic
carcinoma [27]. One LRR in base of skull was salvaged
by re-irradiation using IMRT with acceptable toxicity.
However, data from re-irradiation in adenoid cystic
carcinoma has shown that most of LRRs following re-
irradiation occur within the re-irradiated high-dose re-
gion, therefore more data regarding dose escalation and
delayed toxicity is required [28].
Our study has few limitations. A relatively small num-
ber of patients were studied, due to the rarity of SDC in
our population. Further, PORT fields, techniques and
doses varied somewhat in our study.
Conclusions
SDC of parotid gland is rare and aggressive entity. Des-
pite extensive treatment by parotidectomy, neck dissec-
tion and PORT; a large proportion of patients developed
all-sites recurrences. Base of skull should be included
Fig. 4 a 4- year OS and b 4-year DFS rates for SDC in our cohort
Fig. 3 Magnetic resonance imaging (MRI) face showing recurrent
mass in parotid bed
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Table 2 Previously published studies on salivary duct carcinoma of Parotid gland
Study Patients Parotid SDC LN + PNI HER-2 neu expression PORT Follow-up Mean LRR DM OS
Huang X, et al. [3] 117 M (63.6 %) 7 (63.6 %) 6 (54.5 %) 5 (45.5 %) 9 (81.8) 8 (72.7 %) Dose: 50–60 30 months 2 (18.2 %) 2 (18.2 %) 2-year 75 %
Jaehne M, et al. [4] 50 30 M (60 %) 39 (78 %) 28 (56 %) - - 36 (72 %) 24 months 24 (48 %) 24 (48 %) 66 %
Gilbert MR, et al. [6] 75 53 M (71 %) 62 (83 %) 54 (72 %) 52 (69 %) 23 (31 %) 31 (41 %) 55 months 0 0 3 year 50 %
Johnston ML, et al. [7] 54- 49 (90.7 %) 38 (67 %) - - 48 (89 %) Dose: 60 Gy 68.4 months 16 (29.6 %) 28 (51.8 %) 43 %
Roh JL, et al [8] 56 34 (62 %) 38 (67 %) - - 21 (37.5) 60 months 71 % 44 %
Kim TH, et al. [10] 15 12 M (80 %) 12 (80 %) 9 (60 %) 8 (53.3 %) - 15 (100 %) 38 months 2 (13.3 %) 7 (47 %) 93 %
Shi S, et al. [11] 38 36 M (94.7 %) 38 (100) - - - - 48 months - - 45 %
Kim JY, et al. [12] 35 30 M (85.7 %) 22 (62.9 %) 26 (74.3 %) 12 (34.3 %) - 31 (88.6 %) 36 months 9 (25.7 %) 6 (17.2 %) 55.1 %
Brandwein-Gensler M, et al. [13] 19 - - - 10 (52.6 %) - 30 months - - 68.4 %
Luna MA, et al. [14] 30 19 M (63.3 %) 24 (80 %) 16 (66.7 %) - - - 24 months 16 (66.7 %) 16 (66.7 %) 30 %
Colmenero Ruiz C, et al. [15] 9 7 M (77.8 %) 8 (88.9 %) 3 (37.5 %) - - 7 (87.5 %) 30 months 5 (55.6 %) 3 (33.5 %) 33 %
Delgado R, et al. [16] 15 12 M (80 %) 13 (86.7 %) 2 (13.3 %) - - 9 (60 %) - 5 (33 %) 6 (40 %) 47 %
Guzzo M, et al. [17] 26 14 M (53.8 %) 21 (80.7 %) 15 (57.7 %) - - 17 (65.4 %) 60 months 11 (42.3 %) 12 (46.2 %) 46 %
Hosal AS, et al. [18] 15 7 M (46.7 %) 12 (80 %) 11 (73.3 %) - - 14 (93.3 %) 48 months 8 (53.3 %) 7 (46.7 %) 43 %
Ko YH, et al. [19] 27 16 M (56.3 %) 21 (77.8 %) 10 (37.1 %) - - 19 (70.4 %) 30 months 9 (33.3 %) 15 (55.6 %) 44 %
Afzelius LE, et al. [20] 12 7 M (58.3 %) 12 (100 %) 5 (41.7 %) - - 12 (100 %) 60 months 3 (25 %) 6 (50 %) 42 %
Lewis JE, et al. [21] 26 17 M (65.4 %) 23 (88.5 %) 19 (73.1 %) - - 13 (50 %) 60 months 15 (57.7 %) 11 (43 %) 43 %
Our study 7 2 M (28.6 %) 7 (100 %) 3 (42.9 %) 6 (85.8 %) 2 (28.6 %) 6 (85.8 %) 20.2 months 5 (71.4 %) 3 (42.8 %) 40 %



















routinely in CTV during PORT, and HER-2 neu status
should also be examined routinely in all these patients.
Further, large multi-institutional studies regarding the
role of re-irradiation, systemic chemotherapy, trastuzu-
mab are warranted to suggest optimal treatment ap-
proaches for SDC of parotid gland.
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